Immunomodulatory effects of antimicrobial agents. Part I: Antibacterial and antiviral agents

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 3, 2012, Pages 319-340

  Labro, Marie Thérèse ^a  

^a INSERM   (France)

Author keywords

antifungal agents; antiparasitic agents; immune system; immunomodulation; infections

Indexed keywords

AMINOGLYCOSIDE; ANSAMYCIN DERIVATIVE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETA LACTAM; CELECOXIB; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; MINOCYCLINE; NEOMYCIN; PENICILLIN DERIVATIVE; PLACEBO; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAMYCIN; SULFONAMIDE; SULFONE; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC RHINITIS; ALLERGIC URTICARIA; ANAPHYLACTIC SHOCK; ANEMIA; ANGIONEUROTIC EDEMA; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APLASTIC ANEMIA; ASTHMA; BONE MARROW SUPPRESSION; BORRELIA INFECTION; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; BRONCHOSPASM; BULLOUS SKIN DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHLAMYDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTACT ALLERGY; CROHN DISEASE; CYSTIC FIBROSIS; DIABETIC NEPHROPATHY; DISCOID LUPUS ERYTHEMATOSUS; DRESS SYNDROME; DRUG EFFECT; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; ESCHERICHIA COLI INFECTION; FLU LIKE SYNDROME; GRAFT DYSFUNCTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEMOLYTIC ANEMIA; HUMAN; IMMUNOBLOTTING; IMMUNOMODULATION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; LEUKOPENIA; LUNG DYSPLASIA; LUNG INJURY; MACULOPAPULAR RASH; MALARIA FALCIPARUM; MEASLES LIKE RASH; MULTIDRUG RESISTANCE; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; MYCOPLASMOSIS; NEISSERIACEAE INFECTION; NEUTROPENIA; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; PSEUDOMONAS INFECTION; PSORIASIS; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RICKETTSIACEAE INFECTION; SALMONELLOSIS; SKIN ALLERGY; SKIN DISEASE; SKIN TEST; STEVENS JOHNSON SYNDROME; SYNOVITIS; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREPONEMATOSIS; TUBERCULOSIS; ULCERATIVE COLITIS;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CHILD; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; VIRUS DISEASES;

EID: 84858179477     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.11     Document Type: Review

References (156)

1. Cohen ML. Changing patterns of infectious disease. Nature 406, 762-767 (2000).
2. Casadevall A. The third age of antimicrobial therapy. Clin. Infect. Dis. 42, 1414-1416 (2006).
3. Silverstein MA. History of Immunology. 2nd Edition. Academic Press, San Diego, CA, USA (2009).
4. Grainger Jr TH. A Guide to the History of Bacteriology. Ronald Press, NY, USA (1958).
5. Bulloch W. The History of Bacteriology. Oxford University Press, London, UK (1938).
6. Lechevalier HA, Solotorovsky M. Three Centuries of Microbiology. McGraw-Hill, NY, USA (1965).
7. Bryskier A (Ed.). Antimicrobial Agents: Antibacterials and Antifungals. ASM Press, WA, USA (2005).
8. Wainwright M. Microbiology before Pasteur. Microbiology Today 28, 19-21 (2001).
9. Lindblad WJ. Considerations for determining if a natural product is an effective wound-healing agent. Int. J. Low. Extrem. Wounds 7 (2), 75-81 (2008). (Pubitemid 351678176)
10. Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nature Rev. Microbiol. 9, 889-893 (2011).
11. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
12. Infectious Diseases Society of America. The 10× 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50(8), 1081-1083 (2010).
13. Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J. Antibiot. (Tokyo) 64(6), 413-425 (2011).
14. Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr. Opin. Investig. Drugs. 11(2), 182-191 (2011).
15. Miller AA, Miller PF (Eds). Emerging Trends in Antibacterial Discovery: Answering the Call to Arms. Caister Academic Press, Norwich, UK (2011).
16. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev. Anti. Infect. Ther. 9(9), 775-785 (2011).
17. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob. Agents Chemother. 45(3), 649-659 (2001). (Pubitemid 32182003)
18. Nacar A, Nacar E. Phagotrophic protozoa: A new weapon against pathogens? Med. Hypotheses 70(1), 141-142 (2008). (Pubitemid 350161153)
19. Bowling FL, Salgami EV, Boulton AJ. Larval therapy: a novel treatment in eliminating methicillin-resistant Staphylococcus aureus from diabetic foot ulcers. Diabetes Care. 30(2), 370-371 (2007). (Pubitemid 46198348)
20. van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J. Clin. Epidemiol. 51(8), 703-708 (1998). (Pubitemid 28404365)
21. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr. Opin. Hematol. 15(1), 15-21 (2008). (Pubitemid 350191024)
22. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am. J. Hematol. 84(7), 428-434 (2009).
23. Bousquet PJ, Demoly P, Romano A et al. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy 64, 194-203 (2009).
24. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for drug hypersensitivity reactions. In: Clinical Aspects of Immunology. 2nd Edition. Coombs RRA, Gells PGH (Eds). Davis, PA, USA, 575-596 (1968).
25. Rodilla EM, González ID, Yges EL, Bellido FJ, Bara MT, Toledano FL. Immunological aspects of nonimmediate reactions to beta-lactam antibiotics. Expert Rev. Clin. Immunol. 6(5), 789-800 (2010).
26. Moreno E, Macías E, Dávila I, Laffond E, Ruiz A, Lorente F. Hypersensitivity reactions to cephalosporins. Expert Opin. Drug Saf. 7(3), 295-304 (2008). (Pubitemid 351802829)
27. Khan D, Solensky R. Drug allergy. J. Allergy Clin. Immunol. 125, S126-S137 (2010).
28. Torres MJ, Blanca M. The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med. Clin. North Am. 94(4), 805-820 (2010).
29. Guéant JL, Guéant-Rodriguez RM, Cornejo-Garcia JA, Viola M, Blanca M, Romano A. Gene variants of IL13, IL4, and IL4RA are predictors of beta-lactam allergy. J. Allergy. Clin. Immunol. 123(2), 509 (2009).
30. Huang CZ, Yang J, Qiao HL, Jia LJ. Polymorphisms and haplotype analysis of IL-4 Ralpha Q576R and I75V in patients with penicillin allergy. Eur. J. Clin. Pharmacol. 65(9), 895-902 (2009).
31. Shu X, Gao Y, Linet M et al. Chloramphenicol use and childhood leukaemia in Shanghai. Lancet 2(8565), 934-937 (1987). (Pubitemid 17150285)
32. Sheen YS, Chu CY, Wang SH, Tsai TF. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. J. Dermatolog. Treat. 20(6), 340-343 (2009).
33. Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell's disease). Burns 36(2), 152-163 (2010).
34. Cacoub P, Musette P, Descamps V et al. The DRESS syndrome: a literature review. Am. J. Med. 124(7), 588-597 (2011).
35. Dibbern DA, Montanaro A. Allergies to sulfonamide antibiotics and sulfur-containing drugs. Ann. Allergy Asthma Immunol. 100, 91-100 (2008). (Pubitemid 351238544)
36. Martínez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 78(6), 361-369 (1999). (Pubitemid 29534115)
37. Jang JW, Bae YJ, Kim YG et al. A case of anaphylaxis to oral minocycline. J. Korean Med. Sci. 25(8), 1231-1233 (2010).
38. Bruynzeel DP, Diepgen TL, Andersen KE et al. Monitoring the European standard series in 10 centres 1996-2000. Contact Dermatitis 53(3), 146-149 (2005). (Pubitemid 41297657)
39. Menezes de Pádua CA, Schnuch A, Lessmann H, Geier J, Pfahlberg A, Uter W. Contact allergy to neomycin sulfate: results of a multifactorial analysis. Pharmacoepidemiol. Drug Saf. 14(10), 725-733 (2005). (Pubitemid 41489453)
40. Araújo L, Demoly P. Macrolides allergy. Curr. Pharm. Des. 14(27), 2840-2862 (2008).
41. Blanca-López N, Andreu I, Torres Jaén MJ. Hypersensitivity reactions to quinolones. Curr. Opin. Allergy Clin. Immunol. 11(4), 285-291 (2011).
42. Kulthanan K, Chularojanamontri L, Manapajon A, Dhana N, Jongjarearnprasert K. Cutaneous adverse reactions to fluoroquinolones. Dermatitis 22(3), 155-160 (2011).
43. Vinson AE, Dufort EM, Willis MD, Eberson CP, Harwell JI. Drug rash, eosinophilia, and systemic symptoms syndrome: two pediatric cases demonstrating the range of severity in presentation-A case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline. Pediatr. Crit. Care Med. 11(4), e38-e43 (2010).
44. Faguer S, Kamar N, Fillola G, Guitard J, Rostaing L. Linezolid-related pancytopenia in organ-transplant patients: report of two cases. Infection 35(4), 275-277 (2007). (Pubitemid 47222274)
45. Gorchynski J, Rose JK. Complications of MRSA Treatment: linezolid-induced myelosuppression presenting with pancytopenia. West. J. Emerg. Med. 9(3), 177-178 (2008).
46. Tsuji Y, Hiraki Y, Mizoguchi A et al. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J. Infect. Chemother. 14(2), 156-160 (2008). (Pubitemid 351624464)
47. Labro MT. Influence of Antibacterial Drugs on the Immune System. In: Principles of Immunopharmacology. Nijkamp FP, Parnham, Michael J (Eds). Birkhäuser, Basel, Switzerland, 473-506 (2011).
48. Marjanovi? N, Bosnar M, Michielin F et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol. Res. 63(5), 389-397 (2011).
49. Jantzie LL, Todd KG. Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia-ischemia in neonatal rats. J. Psychiatry Neurosci. 35(1), 20-32 (2010).
50. Kolios G, Manousou P, Bourikas L et al. Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. Eur. J. Clin. Invest. 36(10), 720-729 (2006). (Pubitemid 44393931)
51. Mendez S, Traslavina R, Hinchman M et al. The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob. Agents Chemother. 53(12), 5114-5121 (2009).
52. Piette EW, Werth VP. Dapsone in the management of autoimmune bullous diseases. Dermatol. Clin. 29(4), 561-564 (2011).
53. Wozel VE. Innovative use of dapsone. Dermatol. Clin. 28(3), 599-610 (2010).
54. Kundu R, Sethi N, Ghose A, Chaudhary R. Age old dapsone in the treatment of idiopathic thrombocytopenic purpura-a case report with review. Am. J. Ther. doi:10.1097/ MJT.0b013e3182204fbb (2011) (Epub ahead of print).
55. Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am. J. Hematol. doi:10.1002/ajh.22266 (2011) (Epub ahead of print).
56. de Menthon M, Mahr A. Treating polyarteritis nodosa: current state of the art. Clin. Exp. Rheumatol. 29(1 Suppl. 64), S110-S116 (2011).
57. Tanghetti E, Dhawan S, Green L et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J. Drugs Dermatol. 10(7), 783-792 (2011).
58. Ren YR, Pan F, Parvez S et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS ONE. 3 (12), e4009 (2008).
59. Beeton C, Wulff H, Standifer NE et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl Acad. Sci. USA 103(46), 17414-17419 (2006). (Pubitemid 44788983)
60. Song IH, Hermann K, Haibel H et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann. Rheum. Dis. 70(4), 590-596 (2011).
61. Cottone M, Renna S, Orlando A, Mocciaro F. Medical management of Crohn's disease. Expert Opin. Pharmacother. 12(16), 2505-2525 (2011).
62. Cox NL, Prowse MV, Maddison MC, Maddison PJ. Treatment of early rheumatoid arthritis with rifampicin. Ann. Rheum. Dis. 51(1), 32-34 (1992).
63. Borg AA, Davis MJ, Fowler PD, Shadforth MF, Dawes PT. Rifampicin in early rheumatoid arthritis. Scand. J. Rheumatol. 22(1), 39-42 (1993). (Pubitemid 23064772)
64. Porter JR, Ge J, Lee J, Normant E, West K. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Curr. Top Med. Chem. 9, 1386-1418 (2009).
65. Li H, Zhou Y, Fan F et al. Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases. Intern. Med. 50(16), 1663-1669 (2011).
66. Hernando-Sastre V. Macrolide antibiotics in the treatment of asthma. An update. Allergol. Immunopathol. (Madr) 38(2), 92-98 (2010).
67. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 3, 331-350 (2008).
68. Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365(8), 689-698 (2011).
69. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin. Infect. Dis. 50(4), 473-480 (2010).
70. Ishimatsu Y, Mukae H, Matsumoto K et al. Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin. Chest 138(3), 730-733 (2010).
71. Govi S, Dognini GP, Licata G et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre Phase II trial. Br. J. Haematol. 150(2), 226-229 (2010).
72. Soory M. A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review. Open Dent. J. 2, 5-12 (2008).
73. Naini AE, Harandi AA, Moghtaderi J, Bastani B, Amiran A. Doxycycline: a pilot study to reduce diabetic proteinuria. Am. J. Nephrol. 27, 269-273 (2007). (Pubitemid 47164676)
74. Rempe S, Hayden JM, Robbins RA, Hoyt JC. Tetracyclines and pulmonary inflammation. Endocr. Metab. Immune Disord. Drug Targets 7, 232-236 (2007).
75. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav. Brain Res. 196, 168-179 (2009).
76. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol. Disord. Drug Targets 7, 376-381 (2008).
77. Joks R, Durkin HG. Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs. Pharmacol. Res. 64(6), 602-609 (2011).
78. Richards C, Pantanowitz L, Dezube BJ. Antimicrobial and non-antimicrobial tetracyclines in human cancer trials. Pharmacol. Res. 63(2), 151-156 (2011).
79. Federici TJ. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease. Pharmacol. Res. 64(6), 614-623 (2011).
80. Sermet-Gaudelus I, Renouil M, Fajac A et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med. 5, 5 (2007).
81. Rowe SM, Sloane P, Tang LP et al. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J. Mol. Med. 89(11), 1149-1161 (2011).
82. Paul M, Gafter-Gvili A, Fraser A, Leibovici L. The anti-cancer effects of quinolone antibiotics? Eur. J. Clin. Microbiol. Infect. Dis. 26(11), 825-831 (2007). (Pubitemid 47573386)
83. Al-Trawneh SA, Zahra JA, Kamal MR et al. Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents. Bioorg. Med. Chem. 18(16), 5873-5884 (2010).
84. Hedlund E. The protective effects of b-lactam antibiotics in motor neuron disorders. Exp. Neurol. 231(1), 14-18 (2011).
85. Rothstein JD, Patel S, Regan MR et al. b-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 73-77 (2005). (Pubitemid 40101145)
86. Nizzardo M, Nardini M, Ronchi D et al. Beta-lactam antibiotics offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp. Neurol. 229, 214-222 (2011).
87. Sun S, La Scola B, Bowman VD et al. Structural studies of the Sputnik virophage. J. Virol. 84(2), 894-897 (2010).
88. La Scola B, Desnues C, Pagnier I et al. The virophage as a unique parasite of the giant mimivirus. Nature 455(7209), 100-104 (2008).
89. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 12(6), 509-517 (2011).
90. Bauer DJ. A history of the discovery and clinical application of antiviral drugs. Br. Med. Bull. 41(4), 309-314 (1985). (Pubitemid 16244257)
91. De Clercq E. Antiretroviral drugs. Curr. Opin. Pharmacol. 10(5), 507-515 (2010).
92. De Clercq E. Antiviral Drug Strategies. In: Methods and Principles in Medicinal Chemistry. Raimund Mannhold, Hugo Kubinyi, Gerd Folkers (Eds). Wiley-VCH, Weinheim, Germany, 1-28 (2011).
93. Foote BS, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann. Pharmacother. 45(9), 1085-1093 (2011).
94. Rider TH, Zook CE, Boettcher TL et al. Broad-spectrum antiviral therapeutics. PLoS ONE 6(7), e22572 (2011).
95. Sadler AJ, Williams BRG. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8, 559-568 (2008). (Pubitemid 351913674)
96. Burra P. Hepatitis C. Semin. Liver Dis. 29 (1), 53-65 (2009).
97. Tarbet EB, Larson D, Anderson BJ, Bailey KW, Wong MH, Smee DF. Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice. Antiviral Res. 90(3), 126-133 (2011).
98. Saiag P, Bauhofer A, Bouscarat F et al. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br. J. Dermatol. 161(4), 904-909 (2009).
99. Nokes JD, Cane PA. New strategies for control of respiratory syncytial virus infection. Curr. Opin. Infect. Dis. 21, 639-643 (2008).
100. Zhu Z, Dimitrov AS, Chakraborti S et al. Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. Expert Rev. Anti. Infect. Ther. 4(1), 57-66 (2006).
101. Akay S, Karasu Z. Hepatitis B immune globulin and HBV-related liver transplantation. Expert Opin. Biol. Ther. 8(11), 1815-1822 (2008).
102. Fuji S, Kapp M, Grigoleit GU, Einsele H. Adoptive immunotherapy with virus-specific T cells. Best Pract. Res. Clin. Haematol. 24(3), 413-419 (2011).
103. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J. Antimicrob. Chemother. 62(5), 879-888 (2008).
104. Roujeau J-C, Stern RS. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331, 1272-1285 (1994). (Pubitemid 24333193)
105. Danziger-Isakov L, Mark Baillie G. Hematologic complications of anti-CMVtherapy in solid organ transplant recipients. Clin. Transplant 23(3), 295-304 (2009).
106. Ar MC, Ozbalak M, Tuzuner N et al. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. Transplant Proc. 41(5), 1648-1653 (2009).
107. Rockstroh JK, Lennox JL, Dejesus E et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/ emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin. Infect. Dis. 53(8), 807-816 (2011).
108. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin. Infect. Dis. 27(5), 1321-1322 (1998). (Pubitemid 29242492)
109. Angel-Moreno-Maroto A, Suárez-Castellano L, Hernández- Cabrera M, Pérez-Arellano JL. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J. Infect. 52(2), e39-e40 (2006). (Pubitemid 43137401)
110. Zhang KS, Modi GM, Hsu S. Letter: DRESS syndrome associated with raltegravir. Dermatol. Online J. 17(8), 14 (2011).
111. Leng K, Lonsdorf A, Hartmann M. Fatal outcome of nevirapine-associated toxic epidermal necrolysis. Int. J. STD AIDS 19(9), 642-623 (2008).
112. Balasundaram S, Ranganathan K, Umadevi K et al. Oral lesions associated with nevirapine-related Stevens Johnson syndrome: A report of four cases. J. Oral. Maxillofac. Pathol. 15(1), 39-45 (2011).
113. Popovic M, Shenton JM, Chen J et al. Nevirapine hypersensitivity. Handb. Exp. Pharmacol. (196), 437-451 (2010).
114. Holdiness MR. Contact dermatitis from topical antiviral drugs. Contact Dermatitis 44(5), 265-269 (2001). (Pubitemid 32336997)
115. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J. Antimicrob. Chemother. 62(5), 879-888 (2008).
116. Manfredi R, Sabbatani S. Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function. AIDS 20(18), 2399-2400 (2006). (Pubitemid 44789547)
117. Smith EV, Pynn MC, Blackford S, Leopold DJ. Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu). Br. J. Gen. Pract. 60(571), 133-134 (2010).
118. Hirschfeld G, Weber L, Renkl A, Scharffetter-Kochanek K, Weiss JM. Anaphylaxis after Oseltamivir (Tamiflu) therapy in a patient with sensitization to star anise and celery-carrot-mugwort-spice syndrome. Allergy 63(2), 243-234 (2008).
119. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can. J. Gastroenterol. 23(10), 677-683 (2009).
120. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008). (Pubitemid 351214284)
121. Gao S, Gui XE, Liang K, Liu Z, Hu J, Dong B. HLA-dependent Hypersensitivity Reaction to Nevirapine in Chinese Han HIV-infected Patients. AIDS Res. Hum. Retroviruses doi:10.1089/aid.2011.0107 (2011) (Epub ahead of print).
122. Vitezica ZG, Milpied B, Lonjou C et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 22(4), 540-541 (2008). (Pubitemid 351317299)
123. Teissier E, Zandomeneghi G, Loquet A et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 6(1), e15874 (2011).
124. Silin DS, Lyubomska OV, Ershov FI, Frolov VM, Kutsyna GA. Synthetic and natural immunomodulators acting as interferon inducers. Curr. Pharm. Des. 15(11), 1238-1247 (2009).
125. Kacergius T, Ambrozaitis A, Deng Y, Gravenstein S. Neuraminidase inhibitorsreduce nitric oxide production in influenza virus-infected and gammainterferon-activated RAW 264.7 macrophages. Pharmacol. Rep. 58(6), 924-930 (2006). (Pubitemid 46117745)
126. Lagathu C, Eustace B, Prot M et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther. 12(4), 489-500 (2007). (Pubitemid 47041147)
127. Malizia AP, Vioreanu MH, Doran PP, Powderly WG. HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts. Antiviral Res. 74(1), 72-76 (2007). (Pubitemid 46366008)
128. Gills JJ, Lopiccolo J, Tsurutani J et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res. 13 (17), 5183-5194 (2007). (Pubitemid 47502088)
129. Andre P, Groettrup M, Klenerman P et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl Acad. Sci. USA 95, 13120-13124 (1998). (Pubitemid 28509534)
130. Gupta AK, Li B, Cerniglia GJ et al. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 9, 271-278 (2007). (Pubitemid 46608294)
131. Giardino Torchia ML, Ciaglia E et al. Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. PLoS One 5(6), e11052 (2010).
132. Proudfoot AE, Power CA, Schwarz MK. Anti-chemokine small molecule drugs: a promising future? Expert Opin. Investig. Drugs 19(3), 345-355 (2010).
133. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem. Pharmacol. 77, 1655-1664 (2009).
134. Li J, Chen G, Ye P et al. CCR5 blockade in combination with cyclosporine increased cardiac graftsurvival and generated alternatively activated macrophages in primates. J. Immunol. 186(6), 3753-3761 (2011).
135. Brunner TB, Geiger M, Grabenbauer GG et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol. 26(16), 2699-2706 (2008).
136. Hosseini H, Andre P, Lefevre N et al. Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. J. Neuroimmunol. 118, 233-244 (2001). (Pubitemid 32728357)
137. Pérez-Mercado AE, Vilá-Pérez S. Cytomegalovirus as a trigger for systemic lupus erythematosus. J. Clin. Rheumatol. 16(7), 335-337 (2010).
138. Söderberg-Nauclér C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med. 259(3), 219-246 (2006).
139. Beck-Engeser GB, Eilat D, Harrer T, Jäck HM, Wabl M. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Proc. Natl Acad. Sci. USA 106(49), 20865-20870 (2009).
140. Dreyfus DH. Autoimmune disease: a role for new anti-viral therapies? Autoimmun. Rev. 11(2), 88-97 (2011).
141. Lavrnja I, Stojkov D, Bjelobaba I et al. Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production. Int. Immunopharmacol. 8(9), 1282-1290 (2008).
142. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18(1), 64-76 (2012).
143. Zhao H, Donnelly AC, Kusuma BR et al. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J. Med. Chem. 54, 3839-3853 (2011).
144. Houghton JL, Green KD, Chen W, Garneau-Tsodikova S. The future of aminoglycosides: the end or renaissance? Chembiochem. 11(7), 880-902 (2010).
145. Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs 23(3), 165-174 (2009).
146. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics -part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 81(1), 75-87 (2011).
147. Komuro I, Sunazuka T, Akagawa KS, Yokota Y, Iwamoto A, Omura S. Erythromycin derivatives inhibit HIV-1 replication in macrophages through modulation of MAPK activity to induce small isoforms of C/EBPbeta. Proc. Natl Acad. Sci USA 105(34), 12509-12514 (2008).
148. Mencarelli A, Distrutti E, Renga B et al. Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. Eur. J. Pharmacol. 665(1-3), 29-39 (2011).
149. Golub LM, Greenwald RA. Clinical applications of non-antibacterial tetracyclines. Part II. Pharmacological Research 64(6), 549-630 (2011).
150. Caplan AL. Is disease eradication ethical? Lancet 373(9682), 2192-2193 (2009).
151. Böckle BC, Baltaci M, Ratzinger G, Graziadei I, Vogel W, Sepp NT. Hepatitis C and autoimmunity: a therapeutic challenge (Case Report). J. Intern. Med. 271, 104-106 (2012).
152. World Health Organization. (2008) WHO global burden of disease: 2004 update. www.who.int/healthinfo/global-burden- disease/2004-report-update/en/ index.html
153. The foundations of medical and veterinary virology: discoverers and discoveries, inventors and inventions, developers and technologies. www.asm.org/index.php/membership/ foundations-of-virology.html
154. Some Historical Highlights: Structural Virology and Virology. http://virologyhistory.wustl.edu/highlights. htm
155. Clinical Trial Ceftriaxone in Subjects With ALS. http://clinicaltrials. gov/ct2/show/NCT003 49622?term=Ceftriaxone&rank=4
156. Poliomyelitis. www.who.int/mediacentre/factsheets/ fs114/en